|
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 161.30 EUR | +4.60% |
|
+0.31% | +35.55% |
| 03-09 | Hutchmed (China) says Ipsen initiates market withdrawal and recall of Tazverik in China | RE |
| 03-09 | Hutchmed announces update on licensed oncology product Tazverik in China | RE |
Main competitors
| Consensus | Analysts' target price evolution (4 months) | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Average Target P. | Objective/dr gap | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|---|
 | €143.67 | -6.83% | 15 | ||||||
| $1,214.34 | +20.42% | 29 | ||||||
| $237.29 | -2.18% | 24 | ||||||
| $248.86 | +9.41% | 29 | ||||||
| CHF 364.79 | +9.74% | 19 | ||||||
| CHF 151.21 | -6% | 21 | ||||||
| GBX 219.72 | +13.57% | 21 | ||||||
| $127.22 | +8.63% | 27 | ||||||
| $350.04 | -7.14% | 28 | ||||||
| $156.59 | +6.79% | 27 | ||||||
| DKK 330.95 | +30.04% | 21 | ||||||
| $28.43 | +6.03% | 26 | ||||||
| $62.16 | +2.52% | 25 | ||||||
| $538.11 | +16.76% | 27 | ||||||
| GBX 20.32 | -0.67% | 20 | ||||||
| €98.49 | +29.91% | 23 | ||||||
| ¥9,823.33 | +3.62% | 15 | ||||||
| ¥5,536.87 | -1.43% | 15 | ||||||
| CN¥82.39 | +49.96% | 17 | ||||||
| Average | 1,038.67 | +9.64% | 23 | ||||||
| Weighted average by Cap. | 694.68 | +9.55% | 25 |
- Stock Market
- Equities
- IPN Stock
- Sector Ipsen
- Sector consensus
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition